Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Trial Profile

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Enoblituzumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 06 Mar 2018 Primary end point added, hence focus of the study shifted to efficacy as well. Planned patient number changed from 16 to 32 and study phase changed from phase 0 to phase II.
    • 06 Mar 2018 Planned number of patients changed from 16 to 32.
    • 22 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top